Page 1

Announcement no . 1/2021 2 February 2021 Q1 2020/21 Interim financial results , Q1 2020/21 1 October 2020 - 31 December 2020 ● ● ● Coloplast delivers a good start to the year , guidance for 2020/21 maintained Coloplast delivered 5 % organic growth in the first quarter . Reported revenue in DKK was up by 1 % to DKK 4,738 million . Exchange rate developments decreased revenue by 4 % due to a significant decrease in the value of USD , GBP and several emerging markets currencies , in particular ARS and BRL . ● Coloplast ● Ostomy Care Continence Care Wound & Skin Care Interventional Urology Coloplast A / S Holtedam 1 DK - 3050 Humlebaek , Denmark Company reg . ( CVR ) no . 69749917 Organic growth rates by business area for the first quarter : Ostomy Care 6 % , Continence Care 6 % , Interventional Urology 5 % and Wound & Skin Care 1 % . Chronic Care delivered a satisfactory first quarter , primarily driven by solid growth in Emerging markets and the US . Growth in Europe continues to be negatively impacted by the COVID - 19 outbreak due to lower growth in new patients , particularly in the UK Chronic business . The Interventional Urology business delivered 5 % organic growth , driven by the Men's Health portfolio in the US , which returned to growth as elective procedures continued to recover during Q1 . The Wound and Skin Care business delivered 1 % organic growth in the first quarter . Wound Care in isolation delivered 5 % organic growth driven by Europe and a return to growth in China . The recently launched Biatain® Fiber portfolio contributed positively to the growth , driven by France and Germany . Skin Care and Contract manufacturing detracted from growth due to lower demand as a result of COVID - 19 . Solid momentum in Emerging markets with 16 % organic growth in the first quarter , driven by Ostomy Care and solid performance in China and LATAM as well as phasing of tender deliveries in Russia . EBIT amounted to DKK 1,536 million for Q1 , a 4 % increase , corresponding to an EBIT margin of 32 % against 31 % last year . The development reflects strong cost control during the COVID - 19 outbreak , but also sustained investments in growth opportunities and innovation . ROIC after tax before special items was 44 % for Q1 against 47 % in the same period last year impacted by the acquisition of Nine Continents Medical in November 2020 . The health and safety of the company's employees and continuity of service to customers continue to be the key priority during the pandemic . Conference call Coloplast will host a conference call on Tuesday , 2 February 2021 at 15.00 CET . The call is expected to last about one hour . To actively participate in the Q & A session please call +45 3544 5577 , +44 3333 000 804 or +1 631 913 1422. The participant PIN code is 91604730 # . In Q2 2020/21 , a new share buy - back programme is expected to be launched , totalling DKK 500 million and to be completed by the end of the 2020/21 financial year . Financial guidance for 2020/21 unchanged We continue to expect organic revenue growth of 7-8 % at constant exchange rates . Reported growth in DKK is expected to be 4-5 % . We continue to expect a reported margin in DKK of 31-32 % . The EBIT margin guidance reflects additional incremental investments of up to 2 % of revenue for innovation and sales and marketing initiatives and continued prudent cost management . Capital expenditure is still expected to be around DKK 1.1 billion . The effective tax rate is still expected to be around 23 % . Access the conference call webcast directly here : https://getvisualtv.net/strea m / ? coloplast - x5anj9jpn2 1